% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lutz:275756,
      author       = {M. S. Lutz$^*$ and L. Zekri$^*$ and L. Weßling$^*$ and S.
                      Berchtold$^*$ and J. Heitmann$^*$ and U. M. Lauer$^*$ and G.
                      Jung and H. Salih$^*$},
      title        = {{I}g{G}-based {B}7-{H}3x{CD}3 bispecific antibody for
                      treatment of pancreatic, hepatic and gastric cancer},
      journal      = {Frontiers in immunology},
      volume       = {14},
      issn         = {1664-3224},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2023-00855},
      pages        = {1163136},
      year         = {2023},
      abstract     = {T cell-based immunotherapy has significantly improved
                      treatment options for many malignancies. However, despite
                      these and other therapeutic improvements over the last
                      decades, gastrointestinal cancers, in particular pancreatic,
                      hepatic and gastric cancer, are still characterized by high
                      relapse rates and dismal prognosis, with an accordingly high
                      unmet medical need for novel treatment strategies. We here
                      report on the preclinical characterization of a novel
                      bispecific antibody in an IgG-based format termed CC-3 with
                      B7-H3xCD3 specificity. In many cancer entities including
                      pancreatic, hepatic and gastric cancers, B7-H3 (CD276) is
                      overexpressed on tumor cells and also on the tumor
                      vasculature, the latter allowing for improved access of
                      immune effector cells into the tumor site upon therapeutic
                      targeting. We demonstrate that CC-3 induces profound T cell
                      reactivity against various pancreatic, hepatic and gastric
                      cancer cell lines as revealed by analysis of activation,
                      degranulation and secretion of IL2, IFNγ as well as
                      perforin, resulting in potent target cell lysis. Moreover,
                      CC-3 induced efficient T cell proliferation and formation of
                      T cell memory subsets. Together, our results emphasize the
                      potential of CC-3, which is presently being GMP-produced to
                      enable clinical evaluation for treatment of pancreatic,
                      hepatic and gastric cancer.},
      cin          = {TU01},
      ddc          = {610},
      cid          = {I:(DE-He78)TU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.3389/fimmu.2023.1163136},
      url          = {https://inrepo02.dkfz.de/record/275756},
}